Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy (CHLORODEX)

25 giugno 2026 aggiornato da: CMC Ambroise Paré

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial

Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.

Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.

Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.

This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.

Panoramica dello studio

Descrizione dettagliata

This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.

Participants will be randomly allocated into two groups:

  • Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
  • Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.

To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.

The infusion will start approximately 10-15 minutes before the spinal punction.

In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.

Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.

Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.

No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.

Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.

Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).

Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.

The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Île-de-France Region
      • Paris, Île-de-France Region, Francia, 75016
        • Clinique Drouot Rémusat
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
  • Signed written informed consent form,
  • Affiliation to a social security system,
  • Negative pregnancy test on the day of procedure for non-menopausal patients.

Exclusion Criteria:

  • Contraindications to spinal anesthesia with intrathecal chloroprocaine
  • History of diabetes,
  • Pre-existing peripheral neuropathy,
  • American Society of Anesthesiologists (ASA) physical status IV,
  • Contraindication to dexamethasone,
  • Hypersensitivity of any drug used in this study,
  • Long-term oral corticosteroid therapy,
  • Chronic opioid use,
  • Chronic pain syndromes,
  • Contraindications to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Ketoprofen, Celecoxib)
  • Need for a peripheral nerve block in addition to spinal anesthesia (e.g. knee ligamentoplasty),
  • Mental or linguistic inability to understand the study,
  • Patients under legal protection (guardianship, curatorship or safeguard of justice),
  • Patients currently included or planning to be included in another interventional study,
  • Pregnant or breastfeeding women,
  • Women of childbearing potential not using effective contraception.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: CHLORO
Normal saline solution IV infusion
IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
Spinal anesthesia with chloroprocaine 40 mg
Sperimentale: CHLORODEX
Dexamethasone IV infusion
Spinal anesthesia with chloroprocaine 40 mg
IV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to regression of sensory block by two dermatomes (pin-prick test)
Lasso di tempo: Up to 2 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Up to 2 hours following spinal anesthesia

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to complete resolution of motor block
Lasso di tempo: Up to 8 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).
Up to 8 hours following spinal anesthesia
Time to regression of sensory block by four dermatomes (pin-prick test)
Lasso di tempo: Up to 8 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Up to 8 hours following spinal anesthesia
Maximum sensory block level
Lasso di tempo: Up to 30 minutes following spinal anesthesia
Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).
Up to 30 minutes following spinal anesthesia
Time to maximum sensory block level
Lasso di tempo: Up to 30 minutes following spinal anesthesia
Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).
Up to 30 minutes following spinal anesthesia
Need for additional anesthetic procedure
Lasso di tempo: From spinal anesthesia to the end of surgery
Whether an additional anesthetic procedure was required during surgery, including sedation or conversion to general anesthesia
From spinal anesthesia to the end of surgery
Time to regression of sensory block by two dermatomes (cold test)
Lasso di tempo: Up to 2 hours following spinal anesthesia
Time (in minutes) from spinal puncture to two dermatome sensory regression assessed by a standardized cold test
Up to 2 hours following spinal anesthesia
Incidence of hypotension
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of hypotension, defined as a systolic blood pressure (SBP) < 90 mmHg and/or a mean arterial pressure (MAP) < 65 mmHg and/or a decrease in blood pressure ≥ 30% from baseline
From spinal anesthesia to 24 hours after surgery
Incidence of bradycardia
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of bradycardia defined as a heart rate (HR) < 50 bpm
From spinal anesthesia to 24 hours after surgery
Incidence of nausea
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of nausea reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of vomiting
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of vomiting reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of pruritus
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of pruritus reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of urinary retention
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of urinary retention reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Maximal pain score in the PACU
Lasso di tempo: Up to 6 hours following spinal anesthesia
Maximal pain score collected in the PACU using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain).
Up to 6 hours following spinal anesthesia
Total opioid consumption
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Total opioid consumption, converted to oral morphine equivalents (OME, mg) from the intraoperative period to 24 hours postoperatively, including opioid use at home as reported during the Day 1 follow-up
From spinal anesthesia to 24 hours after surgery
Pain intensity
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Pain intensity at rest and during movement will be assessed using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain). Pain scores will be recorded intraoperatively (H0)in the PACU (H1), during ambulatory hospitalization (H3 and H6), and at home until Day-1 (H9, H12 and H24).
From spinal anesthesia to 24 hours after surgery
Duration of surgery
Lasso di tempo: Intraoperative period
Time (in minutes) between the skin incision and the last suture
Intraoperative period
Incidence of post-puncture headache
Lasso di tempo: From spinal anesthesia to 24 hours after surgery
Any episode of headache reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 settembre 2026

Completamento primario (Stimato)

31 agosto 2028

Completamento dello studio (Stimato)

1 settembre 2028

Date di iscrizione allo studio

Primo inviato

19 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 giugno 2026

Primo Inserito (Effettivo)

29 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Artroscopia del ginocchio

Prove cliniche su Sodium Chloride 0.9%

3
Sottoscrivi